Company profile
A2 Biotherapeutics Inc.
Privately held: no public share price (Privately held clinical-stage cell therapy company; no IPO to date. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.cbinsights.com/company/a2-biotheapeutics/financials]) · United States
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | EGFR (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 2 | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.